selected publications
-
Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
Blood.
2018
Academic Article
GET IT
Times cited: 222 -
Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab.
The Journal of clinical endocrinology and metabolism.
2018
Article
GET IT
Times cited: 131 -
Reappraising the 2016 WHO classification for diffuse glioma.
Neuro-oncology.
2017
Article
GET IT
Times cited: 5 -
Molecular and histologic characteristics of pseudoprogression in diffuse gliomas.
Journal of neuro-oncology.
2016
Academic Article
GET IT
Times cited: 29 -
Is there a role for early chemotherapy in the management of pituitary adenomas?.
Neuro-oncology.
2016
Information Resource
GET IT
Times cited: 27 -
Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas.
Neuro-oncology.
2013
Academic Article
GET IT
Times cited: 25 -
Standardized patient outcomes trial (SPOT) in neurology.
Medical education online.
2011
Academic Article
GET IT
Times cited: 19